These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26499918)

  • 1. Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.
    Ji M; Kim HK; Kim SK; Lee W; Sung H; Chun S; Kim MN; Min WK
    J Clin Lab Anal; 2016 Sep; 30(5):485-9. PubMed ID: 26499918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Value of Vancomycin AUC
    Hanai Y; Hashi H; Hanawa K; Endo A; Miyazaki T; Yamaguchi T; Harada S; Yokoo T; Uekusa S; Namiki T; Yokoyama Y; Asakawa D; Isoda R; Enoki Y; Taguchi K; Matsumoto K; Matsuo K
    Pharm Res; 2024 Jul; 41(7):1381-1389. PubMed ID: 38886259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
    Moise-Broder PA; Forrest A; Birmingham MC; Schentag JJ
    Clin Pharmacokinet; 2004; 43(13):925-42. PubMed ID: 15509186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Britt NS; Patel N; Horvat RT; Steed ME
    Antimicrob Agents Chemother; 2016 May; 60(5):3070-5. PubMed ID: 26953202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
    Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
    Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
    Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
    J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant
    Marko R; Hajjar J; Nzeribe V; Pittman M; Deslandes V; Sant N; Cowan J; Kyermentang K; Ramsay T; Zelenitsky S; Kanji S
    Can J Hosp Pharm; 2021; 74(4):334-343. PubMed ID: 34602621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates.
    Tseng SH; Lim CP; Chen Q; Tang CC; Kong ST; Ho PC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic analysis of vancomycin in patients with
    Tochikura N; Matsumoto C; Iwabuchi S; Aso H; Fukushima S; Ootsuka S; Ooba N; Ishihara M; Nakajima H; Umemura H; Nakayama T
    Eur J Hosp Pharm; 2024 Aug; 31(5):440-446. PubMed ID: 36868850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Fu CF; Huang JD; Wang JT; Lin SW; Wu CC
    PLoS One; 2018; 13(3):e0193585. PubMed ID: 29505620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
    J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous vs. intermittent vancomycin therapy for Gram-positive infections not caused by methicillin-resistant Staphylococcus aureus.
    Duszynska W; Taccone FS; Hurkacz M; Wiela-Hojenska A; Kübler A
    Minerva Anestesiol; 2016 Mar; 82(3):284-93. PubMed ID: 26184702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dosing and monitoring of vancomycin: what is the best way forward?
    Drennan PG; Begg EJ; Gardiner SJ; Kirkpatrick CMJ; Chambers ST
    Int J Antimicrob Agents; 2019 Apr; 53(4):401-407. PubMed ID: 30599240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
    Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
    Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.